

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



BROAD INTELLIGENCE INTERNATIONAL PHARMACEUTICAL HOLDINGS LIMITED

博智國際藥業控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1149)

SUPPLEMENTAL AGREEMENT FOR MAJOR TRANSACTION

Reference is made to the announcement of Broad Intelligence International Pharmaceutical Holdings Limited (the “**Company**”) dated 14 May 2010 (the “**Announcement**”) relating to the Disposal. Capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement unless defined otherwise.

Pursuant to the Share Transfer Agreement, a period of four weeks from the date of the Share Transfer Agreement (the “**Due Diligence Period**”) was allowed for the due diligence to be conducted on the Target Group. As more time is required for the due diligence to be conducted on the Target Group, the Purchaser, the Company and Mr. Zhong entered into a supplemental agreement on 14 June 2010 (the “**Supplemental Agreement**”).

Under the Supplemental Agreement, the parties thereto agreed that:

- a) the Due Diligence Period shall extend for 10 Business Days from the date of the Supplemental Agreement; and
- b) HK\$39,500,000, as refundable deposit, shall be satisfied by way of a cashier order issued by a licenced bank in Hong Kong (or such other form of payment as may be agreed between the parties to the Supplemental Agreement) within 10 Business Days from the date of the Supplemental Agreement.

Save for the Due Diligence Period and the initial payment term set out above, all other terms and conditions of the Share Transfer Agreement shall remain unchanged and continue in full force and effect.

By Order of the Board
Broad Intelligence International Pharmaceutical Holdings Limited
Mr. Zhong Houtai
Chairman

Hong Kong, 14 June 2010

As at the date of this announcement, the Board comprises Mr. Zhong Houtai, Mr. Zhong Houyao, Mr. Lin Supeng and Mr. Yang Ma, all being executive Directors and Mr. Pei Renjiu, Mr. Li Kai Ming and Mr. Cheung Chuen, all being independent non-executive Directors.